Back to Trials
NCT05710380NARecruiting

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

University of Chicago

Start Date

4/26/2023

Completion Date

5/1/2026

Summary

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate. * Voluntary written informed consent before the MRI examination. Exclusion Criteria: * Subjects incapable of giving informed written consent. * Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher; * Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders. * Prisoners. * Minor children (under the age of 18 years old). * Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.

Interventions

OTHER

Risk Map Decision Support System (DSS).

RADIATION

Magnetic Resonance Imaging (MRI)

PROCEDURE

Magnetic Resonance Imaging (MRI) Guided Biopsy

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Prostate CancerProstate AdenocarcinomaProstate Neoplasm

Locations

University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois 60637

United States